76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Verve Therapeutics Inc
Closed
10.91 -0.37
Overview
Share price change
24h
Min
10.9
Max
10.96
Income | 19M -31M |
|---|---|
Sales | 20M 33M |
Profit margin | -94.108 |
Employees | 274 |
EBITDA | 19M -35M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +29.31% upside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | 597M 985M |
|---|---|
Previous open | 11.28 |
Previous close | 10.91 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Verve Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Verve Therapeutics Inc Forecast
Price Target
By TipRanks
29.31% upside
12 Months Forecast
Average 14.25 USD 29.31%
High 24 USD
Low 11 USD
Based on 9 Wall Street analysts offering 12 month price targets forVerve Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
